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region containing spectrin-like repeats, predicted to
give the molecule a rigid, rod-shaped structure. The
N-terminal domain was subsequently shown to bind the
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Dystrophin-Associated ProteinsCharacterization of the mechanisms underlying vari-
The next important piece in the puzzle fell into placeous types of muscular dystrophy has been an out-
when the laboratories of Campbell and Ozawa demon-standing triumph of molecular biology. Increasing
strated that the C-terminal part of the dystrophin mole-clarification of the aberrant cellular processes respon-
cule bound to a complex of novel glycoproteins embed-sible for these conditions may ultimately permit the
ded in the muscle cell membrane. Subsequent workdevelopment of effective means for molecular inter-
from both of these laboratories, and others, has shownvention, allowing correction of the abnormal cellular
that the dystrophin-associated glycoprotein complexphysiology that results in the dystrophic phenotype.
(DPC) contains three subcomplexes of proteins. The
complex is depicted schematically in Figure 1 (for re-Muscular dystrophies are a heterogeneous group of in-
views of the DPC with primary references, see Blake etherited single-gene disorders, characterized clinically
al., 2001; Burton and Davies, 2000): - and -dystrogly-by progressive muscle weakness and wasting. Until re-
can are derived from a single protein precursor by post-cently, this large group of conditions was classified ac-
translational processing. -dystroglycan is a transmem-cording to Mendelian inheritance patterns and clinical
brane protein; the intracellular C-terminal domain bindsfeatures. With the advent of molecular genetic mapping
directly to dystrophin. The extracellular domain oftechniques, however, it became clear that a number of
-dystroglycan binds to -dystroglycan. The latter isclinically similar conditions were linked to an array of
heavily glycosylated, wholly extracellular, and binds todistinct genomic loci. Recent advances in positional
the basement membrane component laminin. This com-cloning, bioinformatics, and candidate gene analysis
pletes a molecular link between the myofiber F actinhave started to elucidate the mechanisms responsible
cytoskeleton and the extracellular matrix (ECM), via dys-for various types of muscular dystrophy and have shed
trophin and - and -dystroglycan.some light onto the (often related) functions of the many
-, -, -, -, -sarcoglycans and sarcospan are inte-different gene products implicated in the etiology of
gral membrane glycoproteins forming a subcomplexthese diseases. Elucidation of molecular pathways in-
that associates with -dystroglycan. The functions ofvolved in the pathogenesis of muscular dystrophy has
the sarcoglycan complex are uncertain. The close asso-enabled the rational conception of strategies aimed at
ciation between sarcoglycans and other members ofalleviating the dystrophic phenotype. Here, we examine
the DPC suggested that mutations in the genes encod-what is known about the molecular pathogenesis of the
ing these glycoproteins might be responsible for othermuscular dystrophies and review strategies aimed at
forms of muscular dystrophy. Loss-of-function muta-averting the muscle degeneration that results from an
tions in genes encoding the sarcoglycans have been
assorted group of primary genetic defects.
shown to cause various types of recessive limb girdle
Dystrophin
muscular dystrophy (LGMD) and severe childhood onset
The first breakthrough in understanding the molecular muscular dystrophy (reviewed in Bushby, 1999). In many
basis for muscular dystrophy happened in 1986. Follow- cases, loss of one component seems to destabilize the
ing a long, multinational effort, the gene defect responsi- entire DPC and lead to disruption of the cytoskeleton–
ble for the common X-linked severe childhood-onset extracellular-matrix link, implying that one function of
Duchenne type of muscular dystrophy (DMD) was estab- SGs might be in maintaining stability of the DPC.
lished by positional cloning techniques, in Kunkel’s lab- - and- syntrophin and-dystrobrevin are intracellu-
oratory. The gene product, dystrophin, is a large cy- lar proteins that associate with the C terminus of dys-
toskeletal protein that is located at the cytoplasmic face trophin. Syntrophin seems to recruit signaling proteins
of the muscle cell plasma membrane. Dystrophin is to the DPC, including nNOS and voltage-gated sodium
missing from the muscles of DMD patients. The milder channels. Novel binding partners of dystrobrevin are
allelic disorder, Becker muscular dystrophy (BMD), is discussed below. No pathogenic mutations have been
caused by mutations that result in reduced expression described in the genes encoding syntrophin or dystro-
of dystrophin, or expression of truncated partially func- brevin.
tional forms of the protein. Analysis of the primary se- Functions of Dystrophin
quence of dystrophin predicted an N-terminal domain The cytoskeleton-dystrophin-dystroglycan-ECM link has
sharing homology with -actinin, and a large central been postulated to perform a mechanical function in
muscle, providing protection for the sarcolemma
against the local forces that develop during muscle con-4 Correspondence: kay.davies@anat.ox.ac.uk
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Table 1. Muscular Dystrophy Can Result from Mutations in Genes
Whose Products Are Not Known to Associate with Dystrophin
or the DPC
Gene product Location Phenotypes
Emerin Nuclear envelope X-EDMD
Lamin A/C Nuclear envelope AD-EDMD
LGMD 1B
Dysferlin Membrane Distal myopathy
LGMD 2B
Caveolin 3 Caveolae LGMD 1C
Calpain 3 Cytoplasm LGMD 2A
Integrin 7 Membrane Congenital myopathy
Collagen VI ECM Bethlem myopathy
DMPK Neuromuscular junction Myotonic dystrophy
ZNF9 Nuclear? PROMM
PABP2 Nuclear OPMD
Telethonin Sarcomeric LGMD 2G
Myotilin Sarcomeric LGMD 1AFigure 1. Schematic Depiction of the Dystrophin-Associated
Complex
Abbreviations: EDMD, Emery-Dreifuss muscular dystrophy; LGMD,
limb girdle muscular dystrophy; DMPK, myotonic dystrophy protein
kinase; PROMM, proximal myotonic myopathy; OPMD, oculopha-traction. In support of this idea, the absence of dys-
ryngeal muscular dystrophy; and PABP2, polyA-binding protein 2.
trophin renders the sarcolemma susceptible to contrac-
tion-induced rupture. One prediction from this is that
defects of other components of the cytoskeleton-ECM part of an intermediate filament network, which links the
link would result in muscle degeneration. This is, in fact, muscle contractile apparatus to the sarcolemma. The
the case; genetic mutations abolishing production of properties and functions of the -DB–syncoilin–desmin
the basement membrane protein laminin give rise to link are unclear at present, but further evaluation may
a congenital form of muscular dystrophy in which the reveal more interesting functions of the DPC. Observa-
phenotype extends to peripheral nerve and central ner- tions such as these imply that the consequences of
vous system pathology. Interestingly, no naturally oc- dystrophin deficiency are complex and may be caused
curring mutations have yet been described in the dys- both by direct loss of its cytoskeletal functions and by
troglycan gene. Mouse dystroglycan null mutations are secondary loss of DPC components. There is some evi-
lethal in early embryogenesis, owing to a failure to form dence that dystrophic muscle fibers have abnormal
an essential extra-embryonic structure, Reichert’s mem- trans-sarcolemmal calcium currents, and higher intra-
brane (Williamson et al., 1997). Muscle-specific loss of cellular calcium concentrations than normal fibers, but
dystroglycan, and antibody-mediated disruption of the there is no universal agreement about the presence or
link between muscle -dystroglycan and laminin, how- nature of such changes, or whether they are primary or
ever, both cause muscular degeneration in mouse mod- secondary to muscle damage from other factors (re-
els, implying that the normal function of DG is essential viewed in Burton and Davies, 2000).
to maintain myofiber integrity (reviewed in Burton and Muscular Dystrophy Not Linked to Loss
Davies, 2000). of Dystrophin or Associated Proteins
Dystrophin almost certainly has functions other than Although many types of muscular dystrophy have been
maintaining the cytoskeleton-ECM link. Secondary loss linked with loss of function of dystrophin and its associ-
of the DPC occurs in dystrophin-deficient muscle. In ated proteins, this is by no means an exclusive mecha-
other circumstances, however, it is possible to dissoci- nism for the production of hereditary muscle degenera-
ate loss of the DPC and loss of dystrophin. Transgenic tion. A series of disparate cellular pathways, whose
mice, which are null for full-length dystrophin but ex- disruption is associated with various forms of muscular
press the C-terminal domain in muscle, maintain the dystrophy, has been identified. Examples are summa-
DPC at the sarcolemma, but develop muscular dystro- rized in Table 1. Interestingly, links have emerged be-
phy. This is consistent with the cytoskeletal-ECM link tween several members of this group. For example, em-
performing a crucial function. However, loss of DPC erin and lamin A/C are both nuclear envelope proteins
components in the presence of a normal cytoskeleton- (reviewed in Nagano and Arahata, 2000), and there is
ECM link can also give rise to muscular dystrophy. For evidence that the membrane-associated proteins dys-
example, although no mutations have been described ferlin and caveolin-3 interact.
in the human -dystrobrevin (DB) gene, -DB null mice Many of the implicated molecules have no obvious
develop dystrophic muscle pathology; the cytoskeleton- link with the DPC at present; some may represent com-
ECM link remains uninterrupted (Grady et al., 1999). This ponents of independent pathways that result in a shared
might be attributable to the absence of the loss of crucial pathological phenotype. Further study will elucidate
signaling molecules from the -DB null complex, but how far downstream from the primary genetic defect
recent data implies that loss of novel cytoskeletal links any biochemical convergence occurs.
may be an important factor. Syncoilin is a newly identi- Posttranscriptional Mechanisms
fied component of the DPC that interacts with both -DB and Muscular Dystrophy
(Newey et al., 2001) and the muscle intermediate fila- An interesting story has emerged from study of the most
common type of hereditary myopathy, myotonic dystro-ment protein desmin (Poon et al., 2001). The latter is
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phy. This autosomal dominant condition is caused by involved in protein modification is provided by heredi-
tary inclusion body myopathy. This is an unusual type ofan expanded trinucleotide repeat sequence in the 3UTR
of the DMPK gene, which encodes a serine/threonine late-onset muscle disease, which is prevalent in Jewish
populations and is caused by mutations in gene encodingkinase. The mutant mRNA is retained within myonuclei,
where it aggregates in discrete foci and may interfere UDP-N-acetylglucosamine-2-epimerase/N-acetylman-
nosamine kinase, the rate-limiting enzyme responsible forwith export of the wild-type mRNA. However, reduced
levels of DMPK protein do not explain the phenotypic sialic acid synthesis (Eisenberg et al., 2001). Sialic acid
residues are a common addition to glycoproteins, and arechanges fully; murine DMPK null mutants do not develop
muscular dystrophy, myotonia, or cataract (although present within O-linked sugar moieties of -dystroglycan.
The absence of the apparatus for their synthesis wouldthey do develop cardiac conduction defects). Interest-
ingly, the expanded triplet repeat causes changes in preclude their addition to nascent proteins. Finally, the
mouse muscular dystrophy mutant, myd, may well sharechromatin structure, reducing expression of a transcrip-
tion factor (six5) encoded at an adjacent genomic locus. a similar pathogenic mechanism. The muscle wasting
phenotype in this animal model is caused by loss-of-Murine six5 null mutants develop cataract, potentially
explaining part of the pleiotropic DM phenotype. Recent function mutations in LARGE (Grewal et al., 2001). The
predicted gene product shows homology to variouswork suggests that muscle wasting and myotonia may
be attributable to a toxic gain of function of the DMPK types of eukaryotic and prokaryotic glycosyltransferase,
and there is secondary loss of -dystroglycan glycosyla-RNA, because of the expanded repeat sequence. The
DM phenotype is reproduced in a mouse model, in which tion in the muscles of myd mice.
New Therapeutic Approachesthe expanded CUG repeat is placed within a transgene
encoding human skeletal actin, which is unrelated to Following elucidation of the molecular basis for DMD,
and some types of LGMD, it was hoped that gene ther-DMPK. Toxic gain of function at the RNA level may
be a general mechanism resulting in this phenotype. apy would enable restoration of a normal muscle pheno-
type by replacing the aberrant cellular copy of the rele-A similar dominant disease to DM (proximal myotonic
myopathy) has been described in patients with an ex- vant gene. It has become apparent that delivery of a
therapeutic transgene to all of the muscles in the bodypanded CCUG tetra nucleotide repeat within the first
intron of the gene encoding a zinc finger transcription is a tall order. In addition, there are important immuno-
logical consequences from expressing a protein in anfactor, ZNF9. This gene is unrelated to DMPK and is not
located near the six5 gene, implying that gain of RNA individual who does not possess a functional copy of
the relevant gene, in that the resulting immune responsefunction is the pathogenic mechanism (reviewed in Tap-
scott and Thornton, 2001). to the “foreign” protein tends to curtail transgene ex-
pression. Further problems include the immune re-Posttranslational Processing
and Muscular Dystrophy sponse to vector components and the special problems
for DMD gene therapy, introduced by the size of thePosttranslational modifications of muscle cell proteins
appear to be just as important as the presence of the dystrophin cDNA (14 kb). Consequently, a series of cre-
ative strategies has been developed to alleviate the pro-correct primary amino acid sequences in ensuring that
essential components of muscle are assembled in an gressive muscle weakness and wasting that character-
izes muscular dystrophy. Many of these approachesorderly fashion and function correctly.
Muscle-eye-brain disease (MEB) is a type of congeni- have been developed with specific types of muscular
dystrophy in mind, whereas others may have generaltal muscular dystrophy associated with loss-of-function
mutations in the gene encoding a glycosyltransferase, applicability.
The function of a missing protein may be undertakenPOMGnT1 (Yoshida et al., 2001). This enzyme is respon-
sible for the addition of N-acetlyglucosamine moieties by a different protein. Two broad strategies have been
conceived to take advantage of this possibility for thera-to O-mannosyl glycoproteins. It is known that sialylated
O-glycosidically-linked oligosaccharides of -dystro- peutic purposes. First, instead of directly replacing the
missing gene product, it may be possible to generateglycan are involved in its interaction with the basement
membrane component laminin, and it has thus been artificial constructs that alleviate muscle pathology by
performing a similar function to the absent protein. Aspeculated that POMGnT1 is the enzyme responsible
for this important protein modification. Furthermore, the simple example is provided by the use of truncated
dystrophin minigenes for virally mediated delivery incongenital muscular dystrophy syndrome, Fukuyama
congenital muscular dystrophy (FCMD), is associated DMD. A more sophisticated approach has been de-
scribed by Ruegg and colleagues, who studied a modelwith specific secondary loss of heavily glycosylated
-dystroglycan (Hayashi et al., 2001). The product of the of congenital muscular dystrophy, the laminin 2 defi-
cient dyw mouse (Moll et al., 2001). Muscle degenerationFCMD gene, fukutin (Kobayashi et al., 1998), has an
unknown function. Fukutin has a homolog in muscle, in this animal results from failure of the interaction be-
tween dystroglycan and the ECM, owing to loss of thefukutin-related protein (FKRP), which is affected by loss-
of-function mutations in another form of congenital mus- important ECM ligand for -dystroglycan. A minigene
based on another ECM component, agrin, was designedcular dystrophy (Brockington et al., 2001), and in a milder
allelic disorder, limb girdle dystrophy type 2I. Both fu- to bind to both (1) other components of the basement
membrane and (2) dystroglycan, thus restoring the DG-kutin and FKRP contain conserved motifs present in
glycosyltransferases, and it remains possible that they ECM link. Transgenic overexpression of the minigene in
the muscles of dyw mice prevented the muscle pathol-are members of this enzyme family.
A further, recently characterized example of a dis- ogy, indicating that a rationally designed, engineered
gene product could replace the function of the missingease-producing mutation in a gene whose product is
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protein. Second, protein replacement might be achieved liver therapeutic transgenes to skeletal muscle would
by increasing the expression of an endogenous homo- allow many of the diseases to be treated either directly
log. Dystrophin has an autosomal paralog, utrophin. The or indirectly by gene therapy, and the development of
latter is expressed at low levels in adult muscle, but at pharmacological methods for manipulating the expres-
much higher levels in fetal muscle, where it is localized sion of endogenous genes might allow alleviation of mus-
to the sarcolemma. The two proteins are functionally cle pathology through enforced upregulation of disease
redundant, as shown in transgenic mouse experiments gene homologs, or downregulation of effector pathways.
in which dystrophin null mice are spared the expected In contrast to the situation two decades ago, we now
muscle degeneration by overexpression of a utrophin at least have an idea of the mechanisms leading to
transgene in muscle (Tinsley et al., 1998). A detailed muscular dystrophy, and the strategies by which we
characterization of the processes regulating utrophin might tackle the resulting aberrant molecular processes.
expression in muscle is currently underway, with the In this regard, there is reason for cautious optimism.
aim of identifying pharmacological means to enforce its
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